Program
HMGB1 Inhibitor SB17170
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by SPARK Biopharma.
Furthest: phase 2, since Dec 17, 20244 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| SPARK Biopharma | 42 open or running | phase 2since Dec 17, 2024 | Aug 25, 2022 | Jun 30, 2027phase 1 · NCT05522868 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2022First study: phase 1 study in Solid TumorFirst studyNCT05522868 · 50 planned · South Korea
- Feb 27, 2023Phase 1 study in Safety IssuesNCT05795192 · 64 enrolled · Korea, Republic of
- Dec 17, 2024Phase 2 study in Idiopathic Pulmonary FibrosisNCT06747923 · 30 planned · South Korea
- Feb 19, 2025Phase 1 study in Drug Drug Interaction (DDI)NCT06846684 · 12 enrolled · South Korea
Ahead
- Jun 30, 2027Primary completion: phase 1 study in Solid TumorNCT05522868
TargetBeta
HMGB1 →read by rule
“An orally bioavailable prodrug of SB1703, a small molecule inhibitor of high mobility group protein B1 (HMGB1), ”NCIt, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06846684Drug Drug Interaction (DDI) · South Korea | 1 | Completed | Jun 10, 2025 | 12 |
| NCT06747923Idiopathic Pulmonary Fibrosis · South Korea | 2 | Recruiting | May 30, 2026 | 30 |
| NCT05795192Safety Issues · Korea, Republic of | 1 | Completed | Feb 29, 2024 | 64 |
| NCT05522868Solid Tumor · South Korea | 1 | Recruiting | Jun 30, 2027 | 50 |
How it is read
Names in the registry
- “SB17170”, 4 entries
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.